Abstracting and Indexing

  • PubMed NLM
  • Google Scholar
  • Semantic Scholar
  • Scilit
  • CrossRef
  • WorldCat
  • ResearchGate
  • Academic Keys
  • DRJI
  • Microsoft Academic
  • Academia.edu
  • OpenAIRE
  • Scribd
  • Baidu Scholar

The Safety and Efficacy of Ultrasound-Accelerated-Catheter-Directedthrombolysis with Urokinase in Patients with Intermediate-High Risk Pulmonary Embolism

Author(s): Hani Al-Terki, Tobias Paulus, Michael Gotzmann, Andreas Mügge

Background: Ultrasound-accelerated-thrombolysis (USAT) represent a safe and effective therapeutic modality in patients with intermediate-tohigh risk pulmonary embolism. The tested thrombolytic agent in all studies investigating USAT in PE patients is alteplase (Actilyse). Actually, there is a lack of supply of alteplase (alteplase®, Boehringer Ingelheim) in Europe.

Methods: Nine patients with intermediate-to-high risk pulmonary embolism were treated with USAT and urokinase (300,000 units per catheter over 10 hours) at our institution. Systolic pulmonary artery pressure, right ventricle function and right ventricle/left ventricle ratio were measured at baseline and after therapy. The primary outcome was the difference in the RV/LV ratio from baseline to 24 hours. Safety outcomes included in-hospital death, major and minor bleeding according to GUSTO bleeding score.

Results: The mean RV/LV ratio was reduced from 1.19±0.11 at baseline to 0.75±0.29 at 24 hours (p=0.003); the systolic pulmonary artery pressure decreased from 52.4±18.7 to 35.11±8.0 mmHg (p=0.021). There was 1 major access-site bleeding and no in-hospital deaths. During a follow-up of 117.8±72.5 days, no recurrent venous embolism occurred.

Conclusion: USAT with Urokinase seems to be safe and effective in patients with intermediate-to-high risk pulmonary embolism with favourable clinical, echocardiographic and laboratory results.

Journal Statistics

Impact Factor: * 3.5

CiteScore: 2.9

Acceptance Rate: 14.80%

Time to first decision: 10.4 days

Time from article received to acceptance: 2-3 weeks

Discover More: Recent Articles

Grant Support Articles

© 2016-2024, Copyrights Fortune Journals. All Rights Reserved!